Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -154.90% is 63% below its 5-year average of -95.01%, around the middle of its 5-year range (-242.18%–-21.15%).
As of the fiscal period ended Tuesday, June 30, 2026. 30.24% below its 12-month average of -118.93%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -154.90%.
RETURN ON EQUITY (ROE)
-154.90%
RETURN ON EQUITY (ROE) AVG TTM
-118.93%
RETURN ON EQUITY (ROE) AVG 3Y
-117.72%
RETURN ON EQUITY (ROE) AVG 5Y
-95.01%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-30.24%
CURRENT VS 3Y AVG
-31.59%
CURRENT VS 5Y AVG
-63.04%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 753 covered companies
CURRENT VS SECTOR MEDIAN
-268.73%
vs the sector median at left
Exagen Inc.
Market Cap
$197.87M
Return on Equity (ROE)
-154.90%
TTM Avg
-118.93%
3Y Avg
-117.72%
5Y Avg
-95.01%
Market Cap
$198.33M
Return on Equity (ROE)
N/A
TTM Avg
620.74%
3Y Avg
332.27%
5Y Avg
266.26%
Market Cap
$197.18M
Return on Equity (ROE)
N/A
TTM Avg
213.11%
3Y Avg
66.34%
5Y Avg
24.75%
Market Cap
$200.96M
Return on Equity (ROE)
N/A
TTM Avg
-280.12%
3Y Avg
-179.90%
5Y Avg
-133.80%
Market Cap
$192.49M
Return on Equity (ROE)
-17.83%
TTM Avg
-11.95%
3Y Avg
-32.11%
5Y Avg
-28.82%
Market Cap
$190.07M
Return on Equity (ROE)
-121.76%
TTM Avg
-56.28%
3Y Avg
-58.50%
5Y Avg
-52.63%
Market Cap
$205.80M
Return on Equity (ROE)
-43.64%
TTM Avg
-68.24%
3Y Avg
-59.30%
5Y Avg
-48.32%
Market Cap
$189.11M
Return on Equity (ROE)
-136.83%
TTM Avg
-43.45%
3Y Avg
-452.04%
5Y Avg
-306.86%
Market Cap
$207.27M
Return on Equity (ROE)
28.68%
TTM Avg
26.59%
3Y Avg
20.62%
5Y Avg
19.74%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Exagen Inc. (XGN) | $197.87M | -154.90% | -118.93% | -117.72% | -95.01% |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $198.33M | N/A | 620.74% | 332.27% | 266.26% |
| Surrozen, Inc. (SRZN)vs › | $197.18M | N/A | 213.11% | 66.34% | 24.75% |
| Alector, Inc. (ALEC)vs › | $200.96M | N/A | -280.12% | -179.90% | -133.80% |
| RxSight, Inc. (RXST)vs › | $192.49M | -17.83% | -11.95% | -32.11% | -28.82% |
| Zentalis Pharmaceuticals, Inc. (ZNTL)vs › | $190.07M | -121.76% | -56.28% | -58.50% | -52.63% |
| Whitehawk Therapeutics Inc (WHWK)vs › | $205.80M | -43.64% | -68.24% | -59.30% | -48.32% |
| Eledon Pharmaceuticals, Inc. (ELDN)vs › | $189.11M | -136.83% | -43.45% | -452.04% | -306.86% |
| Pro-Dex, Inc. (PDEX)vs › | $207.27M | 28.68% | 26.59% | 20.62% | 19.74% |
| Electra Therapeutics Inc. (ETRA)vs › | $208.31M | N/A | N/A | N/A | N/A |
ROE
-154.9%
ROA
-36.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -154.90% |
| 2026-03-31 | -139.73% |
| 2025-12-31 | -114.34% |
| 2025-09-30 | -104.97% |
| 2025-06-30 | -80.73% |
| 2025-03-31 | -242.18% |
| 2024-12-31 | -158.44% |
| 2024-09-30 | -131.54% |
| 2024-06-30 | -98.46% |
| 2024-03-31 | -96.85% |
| 2023-12-31 | -104.38% |
| 2023-09-30 | -118.06% |
| 2023-06-30 | -110.18% |
| 2023-03-31 | -124.67% |
| 2022-12-31 | -111.60% |
| 2022-09-30 | -71.35% |
| 2022-06-30 | -61.03% |
| 2022-03-31 | -40.59% |
| 2021-12-31 | -31.61% |
| 2021-09-30 | -25.61% |
| 2021-06-30 | -21.15% |
| 2021-03-31 | -17.08% |
| 2020-12-31 | -39.88% |
| 2020-09-30 | -37.42% |
| 2020-06-30 | -32.35% |
| 2020-03-31 | -29.48% |
| 2019-12-31 | -21.63% |
| 2019-09-30 | -16.96% |
